Germonpré, P., & Van den Wyngaert, T. (2019). Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. PLoS One.
シカゴスタイル引用形Germonpré, Paul, , Tim Van den Wyngaert. "Second-line Erlotinib After Failure of Pemetrexed-containing Chemotherapy in Advanced Non-small Cell Lung Cancer (NSCLC): Real-world Effectiveness, Safety and Tolerability." PLoS One 2019.
MLA引用形式Germonpré, Paul, , Tim Van den Wyngaert. "Second-line Erlotinib After Failure of Pemetrexed-containing Chemotherapy in Advanced Non-small Cell Lung Cancer (NSCLC): Real-world Effectiveness, Safety and Tolerability." PLoS One 2019.
警告: この引用は必ずしも正確ではありません.